SGLT2 Inhibitors: Basic Training Quiz

The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.


We've been told that SGLT2 inhibitors only work on receptors in the kidneys, but a new study reveals a previously unknown function, as well as a new mechanism of action.

What’s around the corner? Take a peek at 4 technologies in progress aimed at improving diabetes management.

The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?

Metabolic disorders in patients with diabetes place them at particularly high risk for CV morbidity. Find insights on Dx and Tx in these slides.

GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.

Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.

Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.


Subscribe to Diabetes on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.